US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 2.36 against a street estimate of 1.88 — a beat of 25.5%.
Analysts rate Neurocrine Biosciences Inc a buy (22 buy, 3 hold, 0 sell out of 25) with an average price target of $211.09.
| Fund | Stake |
|---|---|
| BlackRock Inc | 13.31% |
| Dodge & Cox | 5.43% |
| JPMorgan Chase & Co | 5.41% |
| AQR Capital Management LLC | 4.91% |
| Vanguard Portfolio Management, LLC | 4.70% |
| Vanguard Capital Management, LLC | 4.49% |
| State Street Corp | 4.33% |
| Two Sigma Investments LLC | 3.04% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-31 |
| Results announced · Q3 2026 | 2026-07-30 |
| Board / officer change · Q2 2026 | 2026-05-28 |
| Material agreement · Q2 2026 | 2026-05-18 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Results announced · Q2 2026 | 2026-05-05 |
| Proxy statement · Q2 2026 | 2026-04-15 |
| Annual report FY2025 | 2026-02-11 |
Readable in the app.
| Announcement | Date |
|---|---|
| Completed acquisition of Soleno Therapeutics for approximately $88.9% ownership stake The company completed its acquisition of Soleno Therapeutics on May 18, 2026, for approximately $2.9 billion. The deal was structured as a tender offer followed by a merger. Key details: 88. | 2026-05-18 |
| Merger agreement announced with Soleno; tender offer and subsequent merger contemplated Neurocrine Biosciences announced a proposed acquisition of Soleno Therapeutics through a tender offer followed by a merger. The deal involves Neurocrine acquiring Soleno's commercial product | 2026-04-06 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Neurocrine Biosciences Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.